Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome inhibitor bortezomib (Velcade) has been successfully used to treat patients with myeloma, drug resistance remains an emerging problem...

Full description

Saved in:
Bibliographic Details
Main Authors: Stessman, Holly A.F., Baughn, Linda B., Sarver, Aaron, Xia, Tian, Deshpande, Raamesh, Mansoor, Aatif, Walsh, Susan A., Sunderland, John J., Dolloff, Nathan G., Linden, Michael A., Zhan, Fenghuang, Janz, Siegfried, Myers, Chad L., Van Ness, Brian G.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4076840/
https://ncbi.nlm.nih.gov/pubmed/23536725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-1151
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items